Evidence map›Paper›PMID 30405786›Full record

ArticleOncology letters2018

MicroRNA 141 represses nasopharyngeal carcinoma growth through inhibiting BMI1.

Fei Liu, Wenjuan Wang, Shuo Li, Qiong Yang, Jing Hu, Nan Zeng, Chunsheng Gao

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Study on effects of miR-141-3p in proliferation, migration, invasion and apoptosis of colon cancer cells by inhibiting Bcl2.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  2. Expression of Circulating MicroRNA-141 in Epithelial Ovarian Cancer.The Malaysian journal of medical sciences : MJMS · 2020
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Fei LiuDepartment of Otolaryngology, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China.
Wenjuan WangDepartment of Otolaryngology, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China.
Shuo LiDepartment of Otolaryngology, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China.
Qiong YangDepartment of Otolaryngology, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China.
Jing HuDepartment of Otolaryngology, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China.
Nan ZengDepartment of Otolaryngology, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China.
Chunsheng GaoDepartment of Otolaryngology, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, Guangdong 518052, P.R. China.
Guangdong Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Distant metastasis is the primary cause of mortality in patients with nasopharyngeal carcinoma (NPC). Unveiling the mechanism of metastasis will aid in shedding light on the clinical therapeutic strategies in NPC treatment. The present study revealed that the expression of microRNA 141 (miR-141) was downregulated in NPC tumor cells, particularly in metastatic ones. Ectopic expression of miR-141 blocked the proliferative and invasive ability of the tumor cells

Indexed as

BMI1metastasismicroRNA-141nasopharyngeal carcinoma

Identifiers

PMID30405786
PMCPMC6202537
OpenAlexW2891636505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.